Pipeline Presentation: David Bearss, CEO, Tolero Pharmaceuticals

Dr. Bearss was a post-doctoral fellow with Dr. Daniel Von Hoff and has extensive experience in small-molecule drug development. Dr. Bearss was on faculty at the University of Arizona from 1999-2003 after which he co-founded Motigen Pharmaceuticals in 2003 and served as Chief Scientific Officer until Monitgen was acquired by SuperGen in 2006. Dr. Bearss has served as Co-director of the Center for Investigational Therapeutics at Huntsman Cancer Institute, Associate Professor in Oncological Sciences at the University of Utah and Associate Professor of Physiology and Developmental Biology at Brigham Young University prior to joining Tolero.

We have worked extensively with Tolero with their lead compound, Alvocidib (formerly known as flavopiridol), in combination with cytarabine and mitoxantrone (FLAM- now known as ACM), in AML. Dr. Bearss is looking to form new collaborations with UNC as well as strengthen existing relationships with Alvocidib.